The eye clinic's recurring visit is being engineered out

Two platform launches in one week, both selling you the operating layer

Sightview announced an updated ophthalmology EHR and practice management platform this week, covered in the trade press and again on the wire as a new technology platform for ophthalmologists. Separately, Roche spent the week explaining what its Ophthalmology Network is and what it is meant to open up. Different companies, different products, one shared assumption: that the eye clinic is a system to be equipped.

The assumption is correct as far as it goes, and incomplete in a way that costs money. Practice management software makes the appointment you already have run better. It schedules it, codes it, bills it, recalls it, and stops it falling through a gap. What it cannot do is create the appointment you never had. A clinic with an excellent record system and an empty Tuesday morning has an expensive Tuesday morning.

The reason to read the vendor announcements anyway is that they show you where the sector believes its problems are. When two platform stories land in the same week as a set of clinical stories that quietly reduce the number of visits per patient, the vendors are busy optimising the throughput of a book that is about to need refilling from the top.

The recurring visit is being engineered out

The clinical news of the week is the part with real commercial consequences. Ophthalmology Times Europe reported that EYP-1901 reduces treatment burden while matching aflibercept on best-corrected visual acuity in wet AMD. On the same days, Healio reported phase 2 results for an intravitreal gene therapy in wet AMD, described in the coverage as incredible.

Set the science aside. It is not your call to make and this is not the place to make it. Read it as a manager instead. The retina service in a private eye clinic is one of the few genuinely predictable revenue lines in the building: a defined cohort, on a fixed interval, for years. It fills sessions nobody has to sell. “Reduced treatment burden” is the clinical phrasing of a commercial fact — fewer of those visits, per patient, per year.

This does not arrive next quarter. Phase 2 is phase 2, and everything between here and a routine change in practice can still go wrong. But planning horizons in a clinic are three to five years — the length of a lease, a laser, a consultant’s contract — and that is exactly the horizon on which a treatment-burden reduction lands. A book that refills itself today will, over that period, need refilling on purpose. The unit that starts to matter is the first appointment: a new patient, with a name and a date, who was not in the system last year.

The first contact is drifting away from the ophthalmologist

Three separate stories this week describe the same drift. Optometrists in Connecticut won Medicaid pay parity with ophthalmology, which is a scope-and-status story wearing a payment story’s clothes. Ophthalmology Advisor reported that optic disc drusen is often missed on computed tomography scans. The same outlet reported that emergency diagnosis is linked to worse outcomes across a range of conditions.

Line them up and the pattern is about routing. More of the first look is happening outside the ophthalmologist’s chair. Some findings are being missed at the imaging step and surfacing later than they should. And a meaningful share of patients are entering care through the emergency route rather than through a booked appointment — the route that, per the reporting, tracks with worse outcomes.

For a private clinic, that routing problem is a demand problem in a clinical coat. Patients who arrive through an emergency department did not fail to find you because your pricing was wrong. Most of them did not know there was a decision to make, or where to take it. That gap is not a marketing invention: it sits between a symptom and a booked first appointment, and it gets filled by whoever answers the search that happens in between.

Healthcare advertising is regulated, and this is the terrain where the regulation and the opportunity happen to agree. You cannot promise an outcome and should not try. You can explain what a symptom warrants looking at, what an appointment involves, what the pathway looks like from the outside and how quickly it can be had. That is information rather than persuasion, it is permitted, and almost nobody publishes it well.

What this does to a private eye clinic’s book

Three consequences, in the order they bite.

The mix shifts before the volume does. Cataract and refractive work is elective and decided in a search. Retina work has historically arrived by referral and by recurrence. If recurrence thins, the elective side has to carry more of the calendar — and the elective side is won or lost on visibility long before anyone picks up the phone.

The field of competition widens. Pay parity for optometry, wherever it lands next, means more providers legitimately answering the first question a patient asks. The first question is where the patient forms an opinion about who is competent, and that opinion rarely gets revisited.

Software will be offered as the answer. Two launches in a single week is a preview of the pitch you will hear all year. Buy the platform if the workflow genuinely needs it. Do not buy it expecting demand.

What I would do this week

Take last month’s new patients — first appointments only, not follow-ups — and write down, for each one, how they actually found you. Not the referral field in the record system; the real route. Then search the three procedures that bill most, plus your city, on a phone rather than the desktop in reception, and count how many of the first-screen results are yours.

If the recurring cohort is holding your calendar up while the elective searches are being answered by somebody else, you have both the deadline and the job.